FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Merck | Gardasil

Merck faces new delay at FDA as Gardasil sales slip


Merck is going to have to wait a little longer to see if its campaign to extend an approval for the cervical-cancer vaccine Gardasil to older women has succeeded with regulators. The pharma giant says that the FDA has extended its review period and Merck now expects a decision by the end of this year.

Currently approved to guard girls and women from 9 to 26, Merck has been pushing a request to bump the top age limit to 45 for the past two years. Last year Merck succeeded in gaining an approval to use Gardasil for boys and men 9 to 26 to prevent genital warts that cause cervical cancer. And Merck has been advocating an approval for older women based on data that the vaccine can prevent precancerous lesions spurred by HPV.

Merck was stiff armed by the agency early on, though, as regulators asked for long-term efficacy data on the vaccine. And Merck delivered, providing four-year data demonstrating an 88.7 percent efficacy rate versus 91 percent at the two-year mark.

Gardasil has been a blockbuster performer in the U.S., but it fell far short of full acceptance and now faces competition from Cervarix. Sales slid 20 percent last year to $1.1 billion. Merck could tap a larger market for the franchise, provided the FDA obliges it with an approval.

- here's the story from the Wall Street Journal

Related Articles:
Report: Only one-third of girls receiving HPV vax
What's stopping girls from getting the HPV jab?
Merck tries again for Gardasil expansion

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Merck   Gardasil  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.